- Home
- OBE vs ESPR Comparison
OBE vs ESPR Comparison
Compare OBE & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBE
- ESPR
- Stock Information
- Founded
- OBE 1979
- ESPR 2008
- Country
- OBE Canada
- ESPR United States
- Employees
- OBE N/A
- ESPR N/A
- Industry
- OBE Oil & Gas Production
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- OBE Energy
- ESPR Health Care
- Exchange
- OBE Nasdaq
- ESPR Nasdaq
- Market Cap
- OBE 391.9M
- ESPR 445.6M
- IPO Year
- OBE N/A
- ESPR 2013
- Fundamental
- Price
- OBE $6.01
- ESPR $2.84
- Analyst Decision
- OBE Buy
- ESPR Buy
- Analyst Count
- OBE 2
- ESPR 6
- Target Price
- OBE $11.50
- ESPR $6.50
- AVG Volume (30 Days)
- OBE 236.1K
- ESPR 6.0M
- Earning Date
- OBE 10-30-2025
- ESPR 11-06-2025
- Dividend Yield
- OBE N/A
- ESPR N/A
- EPS Growth
- OBE N/A
- ESPR N/A
- EPS
- OBE N/A
- ESPR N/A
- Revenue
- OBE $508,849,882.00
- ESPR $268,125,000.00
- Revenue This Year
- OBE N/A
- ESPR $10.59
- Revenue Next Year
- OBE N/A
- ESPR N/A
- P/E Ratio
- OBE N/A
- ESPR N/A
- Revenue Growth
- OBE 1.49
- ESPR N/A
- 52 Week Low
- OBE $3.88
- ESPR $0.69
- 52 Week High
- OBE $6.53
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- OBE 52.32
- ESPR 79.27
- Support Level
- OBE $5.87
- ESPR $2.37
- Resistance Level
- OBE $6.25
- ESPR $2.73
- Average True Range (ATR)
- OBE 0.20
- ESPR 0.17
- MACD
- OBE -0.01
- ESPR 0.03
- Stochastic Oscillator
- OBE 39.00
- ESPR 93.75
About OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.